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Malignant Pleural Mesothelioma
A Population-Based Study of Survival
Michael T. Milano, MD, PhD, and Hong Zhang, PhD, MD
Introduction: This study characterizes the overall survival (OS) and
variables affecting OS in patients with malignant pleural mesothelioma.
Methods: A total of 9701 patients with malignant pleural mesothe-
lioma, diagnosed from 1973 to 2006, were retrospectively analyzed
using the population-based surveillance, epidemiology, and end
results database.
Results: The 6-month, 1-year, and 5-year OS were 55, 33, and 5%,
respectively. Significantly adverse prognostic factors from univari-
ate analyses included older age, male gender, higher tumor grade,
nonepithelioid histology, higher stage, no cancer-directed surgery,
and no radiotherapy. Race was not significant. Patients undergoing
cancer-directed surgery and radiotherapy, when grouped by stage,
histology, or grade, had the best median survival (versus radiother-
apy or surgery alone or no surgery/radiotherapy). From Cox pro-
portional hazards analyses, grade (range, 1–4) was associated with
a hazard ratio (HR) of 1.5 (p  0.0001), and not undergoing
cancer-directed surgery was associated with a HR of 1.4 (p 
0.0001). Male gender and older age were also significantly adverse
factors. Tumor histology (HR  1.5) and nonlocalized stage (HR 
1.3) were significant in a Cox model omitting tumor grade. With
grade and histology included in the Cox model, the HRs of histology
and stage were of smaller magnitude and not significant.
Conclusions: From a population-based registry analysis of patients
with malignant pleural mesothelioma, tumor grade and cancer-
directed surgery seem to have the greatest impact on OS. Although
being amenable to surgery likely reflects more indolent disease
and/or better performance status and cardiopulmonary function, the
significantly favorable impact of surgery, accounting for tumor
grade, histology, and stage, may reflect a therapeutic benefit.
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Histology.
(J Thorac Oncol. 2010;5: 1841–1848)
Malignant mesothelioma is a relatively rare cancer arisingfrom the mesothelial lining of pleura as well as the
peritoneal cavities, tunica vaginalis, and pericardium. Most
(80%) cases arise from the pleural mesothelium, and of
these, most (60–70%) are associated with asbestos expo-
sure.1 Several studies have reported on the epidemiology of
mesothelioma from patients registered in the United States
National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) Program database.1–5 There are pres-
ently 2500 to 3000 malignant mesothelioma cases per year,
mostly among older, white males; the United States incidence
seems to have peaked in the years 2000–2005. The recent
decline in incidence is attributable to declining asbestos
exposure, and this trend is expected to continue.1
Pleural mesothelioma is an often debilitating malig-
nancy with a very poor prognosis, in part because malignant
mesothelioma is often diagnosed when patients become
symptomatic with advanced-stage disease. For untreated dis-
ease, the median survival (MS) is generally less than a year.
Treatment options generally include palliative surgical resec-
tion, radiation therapy, chemotherapy, and/or pleurodesis,
which can palliate symptoms of pain and respiratory decline,
delay symptomatic progression, and/or prolong survival.
Radical, curative-intent multimodality therapy, with ex-
trapleural pneumonectomy, adjuvant hemithoracic radia-
tion therapy, and adjuvant chemotherapy (referred to as
trimodality therapy), can be offered to select few patients
with localized disease and adequate pulmonary and cardiac
function.6,7 In these patients, epithelioid histology (versus
sarcomatoid or mixed histologies), no regional lymph node
involvement, and negative surgical margins are favorable
predictors of survival outcome.8,9 Among patients with fa-
vorable prognostic factors, the MS can be on the order of 4 to
5 years.8,10
This study offers a descriptive, retrospective analysis of
patients with malignant pleural mesothelioma registered in
the population-based SEER database. This study was under-
taken with the goal of better characterizing the overall sur-
vival (OS) of malignant pleural mesothelioma and the risk
factors affecting OS. Recently, there have been several Italian
population-based studies of survival among patients with
malignant pleural mesothelioma.11–13 To our knowledge, this
is the first article in over 20 years14 to analyze the OS of
patients registered in the SEER database with a diagnosis of
malignant pleural mesothelioma, and it currently represents
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the largest survival analysis of patients with malignant pleural
mesothelioma.
METHODS
Patient Database
The SEER Program collects information from popula-
tion-based cancer registries throughout the United States.
Serial registry data are deidentified and submitted to the
National Cancer Institute on a biannual basis. The SEER 17
registries include patients registered from 1973 to 2006. Nine
of the 17 registries date back to 1973–1975, 4 registries date
back to 1992, and 4 registries date back to 2000.
Patients were selected with the SEER Stat case listing
session using the following criteria: SEER database field
“Site rec with Kaposi and mesothelioma”  “mesothelioma”
and SEER database field “Site recode”  “pleura” (n 
9392) or “lung and bronchus” (n  309). Only patients
actively followed were included (i.e., autopsy and death
certificate only cases were excluded). Only cases of malig-
nant mesothelioma were included (i.e., cases registered as
benign were excluded). Patients with pleural mesothelioma
were grouped with patients with lung or bronchus mesothe-
lioma and are referred to as pleural mesothelioma in the
remaining text.
For patients diagnosed from 1973 to 2003, the “SEER
historic Stage A” variable of localized, regional (direct ex-
tension and/or nodal involvement), and distant (distant nodal
sites and/or distant metastases) was used to stage patients. For
patients diagnosed from 2004 to 2006, the “summary stage
2000” variable (also grouped into localized, regional, or
distant subgroups) was used. Histology was classified as
epithelioid, fibrous (including spindled, sarcomatoid, and
desmoplastic mesothelioma and fibrous mesothelioma, not
otherwise specified), biphasic (i.e., mixed histology), or me-
sothelioma, not otherwise specified. The SEER database also
records whether or not a patient has undergone cancer-
directed surgery, which the SEER program considers as any
curative or palliative surgery that removes cancer, excluding
biopsies that remove only a fragment or portion of tumor.
Statistical Analysis
Stata version 9.2 (StataCorp, College Station, TX) was
used for data analysis. Actuarial OS was calculated using the
Kaplan-Meier method. For univariate analyses comparing OS
between subgroups, the log-rank test was used. For multivar-
iate analyses (MVA) assessing the significance and hazard
ratios (HRs) of prognostic variables, Cox proportional haz-
ards models were used.
RESULTS
Patient and Tumor Characteristics
Table 1 summarizes the patient and tumor characteris-
tics of the study patients. The median age at the time of
diagnosis was 72 years. Seventy-four percent are white
males. Most (57%) patients had distant disease.
Mesothelioma tumor grade was not available in 90% of
patients. In the 1970s to 1980s, 5% of patients’ tumors were
TABLE 1. Patient and Tumor Characteristics
N 9701
Age, median (range) 72 (17–103)
39 111 (1%)
40–49 384 (4%)
50–59 1191 (12%)
60–69 2377 (25%)
70–79 3495 (36%)
80 2143 (22%)
Race
White 8894 (92%)
Black 469 (5%)
Other 324 (3%)
Unknown 14 (1%)
Gender
Male 7820 (81%)
Female 1881 (19%)
Year diagnosed
1970s 577 (6%)
1980s 1589 (16%)
1990s 2862 (30%)
2000s 4673 (48%)
Grade
Well differentiated (grade I) 157 (2%)
Moderately differentiated (grade II) 106 (1%)
Poorly differentiated (grade III) 581 (6%)
Undifferentiated; anaplastic (grade IV) 162 (2%)
Unknown 8695 (90%)
Histology
Epithelioid 2079 (21%)
Fibrous subtypesa 776 (8%)
Biphasic (mixed) 424 (4%)
Mesothelioma, NOS 6422 (66%)
SEER stage
Localized 1141 (12%)
Regional 1730 (18%)
Distant 5556 (57%)
Unknown/unstaged 1274 (13%)
Surgery
Performed 2139 (22%)
Radical extentb 480
Less than radical extentb 1183
Not otherwise specified 476
Not performed 7317 (75%)
Unknown 245 (3%)
Radiation
Performed 1459 (15%)
Not performed 8079 (83%)
Unknown 163 (2%)
Radiation and surgery performedc 522 (5%)
Surgery performed; no radiationc 1561 (16%)
Radiation performed; no surgeryc 883 (9%)
No surgery or radiationc 6346 (65%)
a Includes spindled, sarcomatoid, and desmoplastic mesothelioma and fibrous
mesothelioma, NOS (not otherwise specified).
b For primary pleural malignancies, the extent of surgery is characterized by a
general coding scheme. Radical resection in the table refers to SEER codes specifying
“total removal” or “radical” resection. For primary lung malignancies, radical resection
is considered any surgical code describing pneumonectomy.
c Excludes patients with unknown variable(s), and thus totals of those undergoing
surgery versus not undergoing surgery do not equal the total from the rows above and
totals of those undergoing radiation versus not undergoing radiation do not equal the
total from the rows above.
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assigned a grade in the SEER database, whereas in the 1990s
to 2000s, 12% of patients were assigned a grade. Histology
was not explicitly registered in 66% of patients. In the SEER
database, 18% of patients from the 1970s, 29% from the
1980s to 1990s, and 41% from the 2000s were registered with
a specific mesothelioma histology.
Among patients with known tumor grade, there was no
significant difference in the distribution of tumor grade be-
tween white versus nonwhite patients (p  0.20 with 2 test),
male versus female patients (p  0.46), or different decades
(p  0.87). Among patients with known tumor histology,
there was no significant difference in the distribution of tumor
histology between white versus nonwhite patients (p  0.93
with 2 test) or male versus female patients (p  0.22).
Despite significant differences in the histology distribution
between decades (data not shown), no appreciable trends
could be ascertained.
Table 2 shows the tumor grade grouped by histology.
For each histology group, most patients (50%) were clas-
sified as having poorly differentiated, grade 3 disease. For
epithelioid, fibrous subtypes and biphasic mesothelioma his-
tology, 39, 20, and 14%, respectively, were classified as
having well to moderately differentiated, grade 1 to 2 disease
(p  0.0001).
Patient Treatments
Cancer-directed surgery was performed in 22% of pa-
tients, radiation was performed in 15%, and radiation and
surgery were performed in 5%. Most patients underwent a
less than radical-extent surgery (see Table 1 footnote). Thir-
ty-six percent of patients with well to moderately differenti-
ated grade mesothelioma versus 25% with poorly differenti-
ated or undifferentiated/anaplastic grade mesothelioma
underwent cancer-directed surgery (p  0.0008). The per-
centage of patients undergoing radiation did not significantly
differ between grade groups. Neither the percentage of pa-
tients undergoing cancer-directed surgery nor the percentage
of patients undergoing radiation differed significantly be-
tween histology groups.
Patient Survival
The 6-month, 1-year, and 5-year OS of patients with
malignant pleural mesothelioma were 55, 33, and 5%, respec-
tively. Table 3 outlines the univariate analyses of variables
potentially impacting OS. Adverse prognostic factors in-
cluded older age, male gender, higher grade disease, nonepi-
thelioid histology, higher stage disease, no cancer-directed
surgery, and no radiation therapy.
Table 3 also shows the univariate analyses grouped by
stage. Older age was an adverse risk factor for all stages.
Race was not significant for any stage group. A more recent
calendar year of diagnosis was a favorable risk factor among
patients with distant disease (HR  0.994 per year) and an
unfavorable risk factor among those with localized disease
(HR  1.015 per year). For all stages, the variables of grade
(lower grade was favorable), histology (epithelioid was fa-
vorable), and surgery (undergoing cancer-directed surgery
was favorable) were significant. Although undergoing radia-
tion was favorable (significant for regional and distant dis-
ease), the magnitude of benefit in MS was small (2–3
months). Undergoing a more radical resection resulted in a
greater MS among patients with distant disease; a nonsignif-
icant benefit of a more radical resection was also observed
among patients with regional disease. Among patients under-
going radical resection and radiation, the MS was 17.0
months for localized disease (n  14), 18.4 months for
regional disease (n 68), and 17.2 months for distant disease
(n  121).
Table 4 shows the MS grouped by treatment (surgery
and radiation) and tumor grade. Cancer-directed surgery
resulted in an improved OS for all grade groups; these
differences were significant for all but the highest grade.
Radiation resulted an improved OS for all grade groups,
although only significant for poorly differentiated, grade 3
disease. Patients receiving radiation for low-grade disease
had a superior MS versus those not treated with radiation
(difference of10 months), although this was not significant.
With increasing grade, the MS after surgery plus radiation
was 58.0, 13.0, 11.5, and 6.3 months, whereas the MS of
patients receiving no radiation or surgery was 16.8, 10.8, 3.3,
and 2.8 months.
Table 5 shows the MS grouped by treatment (surgery
and radiation) and tumor histology. Cancer-directed surgery
resulted in a significantly (p  0.0001) improved OS for all
histology groups. Radiation resulted in a significantly im-
proved OS for the epithelioid and mixed/biphasic histologies,
albeit with a small incremental benefit in MS (3–4 months).
All variables potentially impacting OS were analyzed
using multivariate Cox proportional hazards analyses, as
shown in Table 6. The variables of surgery plus radiation, no
radiation or surgery, and extent of surgery were omitted
because of covariance with the variable of surgery. Stage was
TABLE 2. Grade versus Histology
Well Differentiated
(Grade 1)
Moderately Differentiated
(Grade 2)
Poorly Differentiated
(Grade 3)
Undifferentiated; Anaplastic
(Grade 4) Unknown
Epithelioid 75 (26%) 39 (13%) 148 (51%) 31 (11%) 1786
Fibrous subtypesa 4 (6%) 9 (14%) 32 (51%) 18 (29%) 713
Biphasic 2 (6%) 3 (8%) 24 (67%) 7 (19%) 388
Unknown (NOS) 76 55 377 106 5808
Percentages reflect percentage of patients with a given histology who have a given grade (excluding patients with unknown variables).
a Includes spindled, sarcomatoid, and desmoplastic mesothelioma and fibrous mesothelioma, NOS (not otherwise specified).
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TABLE 3. Univariate Analyses of Variables Potentially Affecting Survival: Median Survival (M)
All Patients Localized Regional Distant
Age
49 11.6 25.9 12.9 8.6
50–59 11.6 13.4 12.5 10.9
60–69 8.9 11.8 8.2 8.3
70–79 6.5 7.6 6.1 6.5
80 3.7 3.6 3.3 3.7
p 0.0001 0.0001 0.0001 0.0001
Race
White 7.2 9.1 7.5 6.8
Black 5.7 5.0 7.2 5.0
Other 5.9 5.8 6.7 5.2
p (white vs. nonwhite) 0.25 0.058 0.64 0.35
p (white vs. black) 0.27 0.32 0.89 0.31
Gender
Male 6.9 8.6 7.2 6.5
Female 7.7 12.3 8.6 7.0
p 0.0001 0.0001 0.0001 0.0001
Calendar year of diagnosis
1970s 7.2 12.8 7.8 5.5
1980s 7.5 10.9 7.6 6.5
1990s 6.8 8.7 7.7 6.5
2000s 7.1 7.7 7.1 7.0
p 0.51 0.0009 0.59 0.001
Grade
Well differentiated (grade I) 19.3 22.7 19.0 19.3
Moderately differentiated (grade II) 11.6 9.0 10.7 12.7
Poorly differentiated (grade III) 4.7 7.0 7.0 3.9
Undifferentiated; anaplastic (grade IV) 2.7 4.0 4.3 3.2
Unknown 7.2 8.9 7.5 6.8
p (excluding unknown grade) 0.0001 0.0002 0.0001 0.0001
Histology
Epithelioid 11.1 11.4 11.6 11.0
Fibrous subtypesa 4.5 9.9 4.8 3.6
Biphasic 7.2 7.0 9.2 6.3
Unknown (NOS) 7.2 9.0 7.0 6.7
p (epithelioid vs. known others) 0.0001 0.017 0.0001 0.0001
SEER stage
Localized 8.9 8.9 NA NA
Regional 7.4 NA 7.4 NA
Distant 6.7 NA NA 6.7
p (localized vs. regional or distant) 0.0001 NA NA NA
p (distant vs. regional or localized) 0.0001 NA NA NA
Surgery
Cancer-directed surgery 11.4 15.8 11.3 10.7
No cancer-directed surgery 6.0 7.4 5.1 5.2
p 0.0001 0.0001 0.0001 0.0001
Radiation
Yes 8.6 10.1 9.5 7.7
No 6.7 8.8 6.7 6.4
p 0.0008 0.64 0.002 0.033
Extent of surgery
Radical resectionb 15.3 14.9 14.6 15.6
Less than radical resectionb 9.6 15.0 10.3 8.7
Not otherwise specified 12.1 16.6 9.6 11.1
p (omitting NOS) 0.0001 0.60 0.16 0.0001
Radiation and surgery performed 13.0 14.7 15.1 12.2
Surgery performed; no radiation 11.0 13.0 9.9 10.0
Radiation performed; no surgery 6.6 8.4 7.1 5.5
No surgery or radiation 5.9 7.0 5.6 5.9
All p values are calculated from log-rank tests. For the continuous variables of age and year of diagnosis, the log-rank test compared groups as stratified. For age and year of
diagnosis, a univariate Cox regression analysis was also performed; the calculated p values from the Cox regression analyses (data not shown) were similar to those shown for the
log-rank test.
a Includes spindled, sarcomatoid, and desmoplastic mesothelioma and fibrous mesothelioma, NOS (not otherwise specified).
b See footnotes of Table 1 for description of extent of surgery.
SEER, Surveillance, Epidemiology, and End Results.
Milano and Zhang Journal of Thoracic Oncology • Volume 5, Number 11, November 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1844
analyzed in the Cox models using localized disease (com-
pared with regional or distant disease) and distant disease
(compared with localized or regional disease) as separate
variables.
Because relatively few patients had tumor grade and/or
histology registered in the SEER database, separate Cox
models were run excluding grade and histology (8128 pa-
tients were evaluated), excluding grade (2907 patients were
evaluated), excluding histology (903 patients were evalu-
ated), and including grade and histology (361 patients were
evaluated). In all Cox models, older age was a significantly
adverse prognostic factor (with a HR of 1.02 per year). Male
gender was a significantly adverse risk factor (HR  1.23–
1.33) in all Cox models except the one in which histology
was omitted. Grade was significant (p  0.0001), with a HR
1.5 in both models in which grade was included. Histology
was significant (p 0.0001), with a HR1.5 in the model in
which grade was excluded. However, when grade was in-
cluded in the Cox model, histology (with a HR of 1.15) was
not significant. In the Cox model in which grade and histol-
ogy were included, SEER stage was not a significant factor.
In all Cox models, undergoing surgical resection (HR 0.6–
0.7) was a significantly (p  0.0001) favorable factor.
DISCUSSION
This study and others11–19 have shown that malignant
pleural mesothelioma is characterized by a poor OS. From
this analysis, several variables significantly affect OS, al-
though mesothelioma grade and cancer-directed surgery seem
to affect OS to the greatest extent. From Cox analyses, a
higher grade (in increments from 1 to 4) was associated with
a significant (p  0.0001) HR of 1.5, and not undergoing
surgery was associated with a significant (p  0.0001) HR of
1.4 to 1.7 (inverse of 0.59–0.72; Table 6). A younger age at
diagnosis was also significantly favorable (p  0.0001),
consistent with other population-based studies.12,13 Al-
though localized mesothelioma stage likely portends a
more favorable prognosis, and distant mesothelioma stage
a less favorable prognosis, in the Cox models, these
variables were relatively less significant (or not signifi-
cant) and were associated with HRs of smaller magnitude,
compared with tumor grade.
Interestingly, the MS of localized mesothelioma (and
therefore the discrepancy between localized, regional, and
distant stage) seems to have diminished with more recent
decade (Table 3). Reasons for this are difficult to ascertain
and likely attributable to multiple factors that a retrospective
study cannot address. This finding is perhaps counterintuitive,
as it might be expected that improved thoracic imaging
developed in recent decades would result in more accurate
mesothelioma staging and therefore improved survival of
patients with localized disease. However, an alternative con-
sequence of improved imaging technology is that it may
allow for the detection of more biologically aggressive dis-
ease at an earlier stage, which could account for the worse
survival with a more recent diagnosis of localized mesothe-
lioma. Another explanation is that the misdiagnosis of benign
TABLE 4. Median Survival After Surgery and/or Radiation, Grouped by Tumor Grade
Well Differentiated
(Grade 1)
Moderately Differentiated
(Grade 2)
Poorly Differentiated
(Grade 3)
Undifferentiated; Anaplastic
(Grade 4)
Median survivals
Surgery
Cancer-directed surgery 21.6 12.5 7.3 5.1
No cancer-directed surgery 17.0 11.4 3.8 3.2
p 0.012 0.034 0.0001 0.67
Radiation
Yes 30.4 12.0 8.3 4.9
No 19.1 11.5 3.8 2.9
p 0.11 0.70 0.0001 0.12
Radiation and surgery performed 58.0 13.0 11.5 6.3
Surgery performed; no radiation 19.7 12.0 6.1 3.0
Radiation performed; no surgery 19.0 11.5 7.7 4.3
No surgery or radiation 16.8 10.8 3.3 2.8
TABLE 5. Median Survival After Surgery and/or Radiation,
Grouped by Tumor Histology
Epithelioid
Fibrous
Subtypesa
Mixed/
Biphasic
Median survivals
Surgery
Cancer-directed surgery 14.9 9.8 9.9
No cancer-directed surgery 8.9 3.2 5.5
p 0.0001 0.0001 0.0001
Radiation
Yes 14.2 5.0 8.9
No 10.2 3.9 6.2
p 0.0001 0.91 0.018
Radiation and surgery performed 18.5 11.0 13.8
Surgery performed; no radiation 13.5 9.6 8.8
Radiation performed; no surgery 8.2 4.3 5.8
No surgery or radiation 9.0 2.3 5.4
a Includes spindled, sarcomatoid, and desmoplastic mesothelioma and fibrous
mesothelioma, NOS (not otherwise specified).
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conditions as malignant mesothelioma (discussed below) is
more likely to have occurred in earlier decades.
Tumor histology (HR 1.5) was significant in the Cox
model omitting grade, although its HR was reduced (1.15)
and not significant after incorporating grade into the Cox
model (albeit with far few patients evaluable). From many
studies, histology is a highly significant prognostic factor for
mesothelioma,9,11–13,15–22 and perhaps the discrepancy of data
from this study versus other studies reflects, in part, the
covariance of histology and grade and/or other confounding
biologic variables. Epithelioid tumors were significantly (p
0.0001) more likely to be lower grade (Table 2). A study from
Memorial Sloan Kettering demonstrated that mesothelioma
histology (HR  1.7, p  0.001) is associated with a greater
and more significant HR than cancer stage (HR  1.2, p 
0.1).18 In a multi-institutional study of patients undergoing
resection for mesothelioma, stage and histology had similar
HRs (1.3–1.4).22
It must be acknowledged that there are complexities
and uncertainties in the pathologic diagnosis of mesotheli-
oma, which therefore limits the interpretation of retrospective
analyses such as this study. A Swedish study demonstrated
that mesothelioma is more likely to be classified as biphasic
subtype if a larger biopsy sample is obtained; the authors
suggest that low-grade disease should reflect relatively indo-
lent variants of epithelial mesothelioma and higher grade
disease more aggressive epithelioid, sarcomatoid, or bi-
phasic types.23 In this study, the increase in the recording
of grade and histology in more recent decades may be
partially attributable to the more recent use of immunohis-
tochemistry for differentiating mesothelioma from other
malignancies and benign conditions and for characterizing
mesothelioma subtypes.24,25
Several studies have shown that male gender is an
adverse prognostic factor for OS.13,16–18 In this study, male
gender was associated with a significantly (p  0.0001)
worse OS on univariate analyses for each stage group, albeit
with a MS decrement (versus females) of 4 months, 6
weeks, and 2 weeks for localized, regional, and distant
stage, respectively (Table 3), and an adverse HR of 1.1–1.3
with Cox analyses (although not significant in Cox model
omitting histology). Although white race was significantly
TABLE 6. Cox Proportional Hazards Analyses of Variables Potentially Affecting Overall Survival
Cox Model
Omit Grade
and Histology Omit Grade Omit Histology All Variables
Patients analyzed 8128 2907 903 361
Age: older age (per year)
HR (confidence interval) 1.021 (1.019–1.023) 1.020 (1.016–1.024) 1.019 (1.012–1.026) 1.023 (1.011–1.035)
p 0.0001 0.0001 0.0001 0.0001
Race: white (vs. all others)
HR (confidence interval) 0.913 (0.841–0.992) 1.058 (0.910–1.231) 0.954 (0.753–1.209) 1.517 (0.954–2.412)
p 0.031 0.46 0.70 0.078
Gender: male
HR (confidence interval) 1.232 (1.161–1.307) 1.329 (1.199–1.473) 1.100 (0.933–1.298) 1.319 (1.008–1.724)
p 0.0001 0.0001 0.26 0.043
Year diagnosed (per year)
HR (confidence interval) 0.992 (0.989–0.995) 1.002 (0.996–1.008) 0.994 (0.983–1.005) 0.999 (0.978–1.022)
p 0.0001 0.46 0.30 0.97
Grade: higher grade
HR (confidence interval) Not analyzed Not analyzed 1.585 (1.465–1.715) 1.548 (1.364–1.756)
p 0.0001 0.0001
Histology: nonepithelioid
HR (confidence interval) Not analyzed 1.511 (1.388–1.645) Not analyzed 1.148 (0.861–1.532)
p 0.0001 0.35
SEER stage (localized vs. distant/regional)
HR (confidence interval) 0.805 (0.752–0.862) 0.764 (0.668–0.873) 0.983 (0.761–1.270) 0.844 (0.554–1.286)
p 0.0001 0.0001 0.90 0.43
SEER stage (distant vs. localized/regional)
HR (confidence interval) 0.978 (0.922–1.037) 1.059 (0.960–1.169) 1.196 (1.003–1.425) 1.118 (0.836–1.496)
p 0.47 0.26 0.046 0.46
Surgery
HR (confidence interval) 0.664 (0.627–0.704) 0.586 (0.535–0.642) 0.718 (0.610–0.846) 0.615 (0.476–0.794)
p 0.0001 0.0001 0.0001 0.0001
Radiation
HR (confidence interval) 1.045 (0.980–1.115) 1.049 (0.940–1.171) 0.772 (0.645–0.923) 0.936 (0.694–1.261)
p 0.18 0.39 0.005 0.67
HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
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favorable with univariate analyses, its affect on OS varied
between the different Cox models and was a nonsignificantly
adverse prognostic factor (HR  1.5, p  0.078) in the Cox
model including grade and histology. Among patients with
known grade and/or histology, there were not significant
differences in the distribution of grade or histology among
patients of different race to account for the discrepancy of
HRs between the different Cox models. Perhaps, among those
patients for whom tumor grade and/or histology was not
available (most of the patients in this study), the distribution
of adverse pathologic features was skewed toward nonwhite
patients. Calendar year of diagnosis was not significant in
Cox models incorporating tumor grade and/or histology,
consistent with other population-based studies showing that
the calendar year or era of diagnosis is not significant.11–13
The benefit of surgical resection on OS has been dem-
onstrated by us and others,18 although other studies suggest a
benefit only in local recurrence, but not OS, after sur-
gery.9,26,27 The observed OS benefit of cancer-directed sur-
gery for pleural mesothelioma likely reflects a combination of
selection of patients who can tolerate surgery, more indolent
disease being amenable to surgical resection, and a therapeu-
tic benefit from surgery. The Cox analyses that incorporate
tumor grade, histology, and stage account for the extent and
aggressiveness of the tumor (albeit with a spectrum of disease
extent included within each stage group), and thus these
analyses do suggest a possible therapeutic benefit of surgery.
Other factors used to select patients for surgery, such as
performance status, pulmonary function, cardiac function,
and comorbid conditions, were not accounted for in our
analyses and also likely contribute to the survival benefit of
surgery. A recent SEER analysis of patients with abdominal
mesothelioma has also shown an OS benefit after surgery.28
Interestingly, the benefit of radical versus less than
radical resection was significant only for patients with distant
disease (Table 3). Presumably, the benefit seen with distant
disease reflects patient selection and/or more accurate staging
after resection, although conceivably select patients with
metastatic disease may benefit from aggressive debulking.
Another explanation is that some patients may have been
inaccurately staged as having had distant disease based on
criteria for lung cancer (i.e., positive pleural cytology). Be-
cause of the retrospective nature of this study, it is not
appropriately designed to address how extent of resection
impacts outcome.
Univariate analyses in this study suggest that undergo-
ing radiation seems to offer a significant OS benefit for
regional and distant disease (Table 2), poorly differentiated
mesothelioma (Table 4), and epithelioid or mixed/biphasic
histologies (Table 5). In the Cox analyses, undergoing radi-
ation was only significant in the Cox model that included
grade but omitted histology (HR of 1.3 for not undergoing
radiation). The best MS was observed among the patients
undergoing cancer-directed surgery and radiation (Tables
3–5), particularly patients undergoing radical resection and
radiation. Although several studies suggest that adjuvant
radiation after pleurectomy29 or extrapleural pneumonec-
tomy10,22,30,31 may favorably impact OS, other studies have
not demonstrated adjuvant radiation to afford an OS bene-
fit,21,32,33 albeit not with as large of a cohort of patients as in
this study nor with a direct comparison of treatment groups.
At least two population-based studies from Italy have dem-
onstrated no significant benefit of any treatment (surgery
and/or radiation) for mesothelioma.11,13
Weaknesses of this study include the retrospective
nature of the study and the inability to account for other
relevant variables, such as performance status,15–17,19 weight
loss,17,19,20 hematological abnormalities,16,17,19,20 lactate de-
hydrogenase levels,19 presenting symptoms,15,17–19 or expo-
sure to tobacco and/or asbestos.18,20 Other weaknesses of this
study include the lack of reported grade and histology in most
patients, despite95% having pathologic diagnosis (data not
shown), and lack of specific information on disease extent.
The tumor pathology cannot be systematically reviewed,
using modern immunohistochemistry techniques, to verify
and specify the pathologic diagnosis. Whether patients were
treated with curative-intent versus palliative-intent therapy
cannot be determined. Presumably, most of the patients
received palliative-intent therapy; only 5% of all patients and
4% of patients with localized disease (data not shown) un-
derwent radiation and surgery. Also, one cannot determine
who received chemotherapy or what chemotherapy agents
were delivered nor can one determine the radiation dose or
radiation fields. Some patients may have received radiation to
the drain sites only.34,35 Another weakness of this study is that
mesothelioma is a rare malignancy for which patients are
often referred to specialized centers, many of which do not
register cases with the SEER program. Thus, this analysis
may not accurately reflect the outcomes of patients referred to
these specialized centers.
The strengths of the study include the large number of
patients analyzed from an unbiased population-based regis-
try. Because of the large numbers of patients, variables such
as race, pathologic histology and grade, gender, age, under-
going radiation, and undergoing surgical resection could be
analyzed.
CONCLUSIONS
From a hypothesis generating, retrospective, popula-
tion-based registry analysis of malignant pleural mesotheli-
oma patients, tumor grade, histology, and cancer-directed
surgery seem to have the greatest impact on OS. When
incorporating grade in a Cox proportional hazards model,
histology is no longer significant, suggesting that grade may
be more prognostic. Although being amenable to surgery
likely reflects more indolent disease and/or better perfor-
mance status and cardiopulmonary function, the significantly
favorable impact of surgery, when accounting for tumor
grade, histology, and stage, may reflect a therapeutic benefit.
Future prospective trials, stratified by patient and tumor-
related factors, could perhaps better define the optimal treat-
ment. Although accruing patients with rare diseases, such as
mesothelioma, into prospective trials is often challenging,
efforts are being made to enroll patients into studies striving
to better understand the role of trimodality therapy.6
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